Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does fluoxetine exacerbate Parkinson's disease?

C F Caley1, J H Friedman

  • 1University of Rhode Island, Cranston.

The Journal of Clinical Psychiatry
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammation and fatigue in early, untreated Parkinson's Disease.

Acta neurologica Scandinavica·2018
Same author

Thoughts on fatigue in Parkinson's disease (and other disorders).

European journal of neurology·2016
Same author

Multiple re-challenges for clozapine neutropenia in Parkinson's disease.

Parkinsonism & related disorders·2016
Same author

Parkinson disease psychosis: Update.

Behavioural neurology·2012
Same author

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Neurology·2012
Same author

Is fatigue in early Parkinson's disease a minor inconvenience or major distress? The answer is 'Yes!'.

European journal of neurology·2012

Fluoxetine (up to 40 mg/day) generally does not worsen parkinsonism in Parkinson's disease patients. Further research is needed to explore fluoxetine for depression in this population.

Area of Science:

  • Neurology
  • Psychiatry

Background:

  • Fluoxetine use in Parkinson's disease (PD) patients requires caution due to potential parkinsonism exacerbation.
  • Limited data exists on fluoxetine's safety and efficacy in PD patients with depression.

Purpose of the Study:

  • To evaluate the effect of fluoxetine on parkinsonian signs and symptoms in outpatients with Parkinson's disease.
  • To assess the safety and tolerability of fluoxetine in this patient population.

Main Methods:

  • Retrospective review of medical records for 23 outpatients with Parkinson's disease treated with fluoxetine.
  • Parkinsonism severity was assessed using the Northwestern University Disability Scale.
  • Depression was evaluated globally, not with a formal scale.

Main Results:

Related Experiment Videos

  • Twenty out of 23 patients (87%) showed no worsening of parkinsonism while on fluoxetine (up to 40 mg/day).
  • Three patients experienced mild parkinsonism worsening, with unclear causality to fluoxetine.
  • Two patients exhibited improvement in parkinsonian signs during fluoxetine treatment.

Conclusions:

  • Fluoxetine, at doses up to 40 mg/day, appears safe regarding parkinsonism in Parkinson's disease outpatients.
  • Further investigation into fluoxetine for treating depression in Parkinson's disease patients is warranted.